Aldeyra plans to request a Type A meeting and currently does not intend further clinical trials, asserting rapid-onset ...
FDA rejection was attributed to a lack of substantial evidence of efficacy, including inconsistencies that undermined ...
An FDA complete response letter for idebenone in LHON indicates unresolved NDA deficiencies and necessitates additional data ...
The goal is to improve public understanding of the FDA decision-making process. (HealthDay News) — The U.S. Food and Drug Administration has published more than 200 complete response letters, or ...
Lexicon Pharmaceuticals announced that it received a complete response letter (CRL) from the FDA regarding its New Drug Application for Zynquista™ (sotagliflozin), which was proposed as an adjunct to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results